Kewaunee Sci Reports FY26 Results; Margins Remain Under Pressure Despite Top-Line Growth

What happened

Kewaunee Scientific Corporation announced fiscal year and fourth quarter results for the period ended April 30, 2026, though the release provided no specific financial figures, leaving investors to infer the outcome from the company's prior guidance and backlog trends. The DeepValue master report identifies the company as a potential buy at $39.10, citing a low valuation of ~9.5x trailing EPS and ~5.1x EV/EBITDA, supported by a near-record backlog of $192.9 million and expectations that FY26 unadjusted EBITDA will exceed FY25. However, the narrative has shifted from a 'surprise growth winner' to one of 'growth but increasingly volatile profitability,' as net income has declined despite strong revenue growth, due to higher operating and interest expenses tied to the Nu Aire acquisition and corporate investments. The stock has fallen roughly 33% over the past year, reflecting investor skepticism about earnings quality and margin stability, even as top-line growth remains robust. The critical question is whether the upcoming quarterly prints will confirm management’s guidance and demonstrate that margin erosion is transient, or whether structural cost pressures will continue to impair earnings.

Implication

For current holders, the FY26 announcement without hard data forces continued reliance on management's prior guidance, but the stock's de-rating to ~9.5x earnings already discounts considerable pessimism. If upcoming quarters show unadjusted EBITDA exceeding FY25 as promised, the current multiple could re-rate toward 12-14x, supporting fair value near $50 (28% upside). However, if backlog continues to erode from the $192.9M level or net debt/EBITDA drifts above 2.5x, the bear case of $30 (23% downside) becomes more likely. The absence of granular disclosure in this press release suggests management may be managing expectations cautiously, which is a positive signal of realistic communication. New investors should wait for concrete evidence of margin stabilization and interest expense reduction from the December 2025 refinancing before initiating or adding to positions. The attractive entry point of $36 identified in the master report remains a potential accumulation zone if shares dip further on any negative sentiment from this vague release.

Thesis delta

The master report's base case assumed FY26 EBITDA would exceed FY25, but the lack of confirmatory details in this FY26 results announcement introduces uncertainty, shifting the burden of proof to future quarterly filings. The thesis now hinges on whether Q3 and Q4 FY26 prints—expected within the next 6 months—will validate management's guidance and demonstrate that margin compression is transitory, or whether structural cost headwinds from Nu Aire integration will persist, necessitating a reassessment of the 'Potential Buy' rating. The stock's significant drawdown already reflects skepticism, but without hard data, the risk/reward remains balanced until tangible evidence of earnings recovery emerges.